Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 16/20 | 0.42 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19798632 | 0.79 | HSD11B1 (0.42) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL28067737 | 0.78 | HSD11B1 (0.41) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL20129585 | 0.76 | GRM5 (0.41) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL7604397 | 0.76 | HSD11B1 (0.37) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL28944812 | 0.76 | CHRNB2 (0.45) | HSD11B1EPHX2SLC6A3 | |
| SCHEMBL14859427 | 0.76 | CHRNB2 (0.45) | HSD11B1EPHX2SLC6A3 | |
| SCHEMBL17317458 | 0.75 | HSD11B1 (0.45) | HSD11B1HSD11B2EPHX2SLC6A3 | |
| SCHEMBL10137646 | 0.75 | HSD11B1 (0.40) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL2450615 | 0.75 | HSD11B1 (0.39) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL3098791 | 0.75 | HSD11B1 (0.39) | HSD11B1HSD11B2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358451-B2 | Heterocycles useful as IDO and TDO inhibitors | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2019-07-23 | — | — | US | disclosed |
| US-20180127418-A1 | HETEROCYCLES USEFUL AS IDO AND TDO INHIBITORS | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| US-20180127418-A1 | HETEROCYCLES USEFUL AS IDO AND TDO INHIBITORS | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| WO-2016165613-A1 | HETEROCYCLES USEFUL AS IDO AND TDO INHIBITORS | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127418-A1 | HETEROCYCLES USEFUL AS IDO AND TDO INHIBITORS | IDO1, IDO2, TDO2 | HSD11B1 771/4885HSD11B2 704/4885EPHX2 519/4885 |
| US-10358451-B2 | Heterocycles useful as IDO and TDO inhibitors | IDO1, IDO2, TDO2 | HSD11B1 771/4885HSD11B2 704/4885EPHX2 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.